SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as traders assess market volatility amidst concerns about regional banks and the potential for a trade war with China. Community discussions revolve around potential support levels and whether the market will experience a significant downturn or a bounce. Increasing VIX levels and rising gold prices add to the uncertain outlook, with some participants bracing for a potential market correction.

ZenaTech, Inc. is an enterprise software technology company, which specializes in mission-critical cloud-based applications integrated with smart hardware to deliver solutions across diverse industries. The firm also develops drone manufacturing, sales, and distribution business. The company was founded by Shaun A. Passley on August 31, 2017 and is headquartered in Vancouver, Canada.

ZenaTech Inc.

ZenaTech is trending due to its plans for congressional meetings to promote drone technology and US manufacturing, sparking community interest in its potential impact on securing funding and shaping policy. Community members are discussing the company's strong management, vision, and possible comparison to Droneshield's growth, while highlighting the increasing US government spending on defense drone contracts. The company's focus on AI drones in the growing defense sector is also a key talking point.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms (BITF) is trending due to a recently announced offering of convertible senior notes, initially $300M then increased to $500M, intended to fund corporate needs and hedge against share dilution. While some investors express concerns about potential dilution and management decisions, others view the capital raise as a strategic move to fund expansion into AI and high-performance computing (HPC). The community is actively debating the offering's terms, potential impact, and the company's long-term prospects in the crypto mining and AI sectors.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as the stock recently hit new highs, sparking discussions about its valuation and future potential. While some community members are taking profits after the surge, others remain bullish, citing upcoming catalysts and long-term growth prospects. Increased trading volume and volatility have also fueled debates between bulls and bears regarding potential pullbacks and continued upward momentum.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing increased volatility as traders weigh geopolitical concerns, banking sector jitters, and potential impacts from upcoming economic reports. Community members are actively discussing potential downside risks and hedging strategies, while also debating whether the current market dip presents a buying opportunity or signals a larger correction.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders discuss potential market volatility amidst concerns about trade tensions and economic uncertainty. Community members are actively debating whether to buy, sell, or hold, with some anticipating a significant market downturn while others express skepticism. The ETF's movements are being closely watched as a hedge against broader market risks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors assess its shift from Bitcoin mining to AI cloud infrastructure, particularly after closing a significant convertible notes deal. The community is discussing the company's potential for growth in the AI sector, its partnership with NVDA, and whether recent price pullbacks present a buying opportunity, alongside debates about its valuation.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending downwards as the community debates whether it's a scam or a buying opportunity, with some pointing to the CEO's past sale of shares as a negative signal. Discussions include potential price targets, upcoming earnings, and the overall valuation of the quantum computing sector. Bears anticipate a significant drop, while bulls hope for a rebound, contributing to the stock's volatility.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending amidst discussions about its positioning in the rare earth element (REE) sector and potential government interest. Community members are weighing perspectives on the stock's valuation, recent price action, and the potential impact of U.S.-China trade dynamics on the REE market. The company's uranium assets and production capabilities are also being considered as factors influencing its future performance.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community debates its role as a safe haven asset amid broader market volatility and a surge in gold prices; recent price action has spurred discussions about potential support levels and future market direction. Mixed sentiment prevails, with some traders pointing to technical indicators suggesting a potential bounce, while others express concern about potential further declines. Community members are actively discussing the impact of large short positions and potential market manipulation.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?

Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Shares of Aquestive Therapeutics jumped more than 11% in after-hours trading Thursday after CEO Dan Barber said the company’s oral epinephrine film, Anaphylm, could become a “blockbuster” drug with as much as $1 billion in peak global sales.Barber&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/09/25/aquestive-ceo-on-its-potential-1-billion-blockbuster-product.html">said in an interview</a> on CNBC’s "Mad Money" with Jim Cramer, noting that despite winning six FDA approvals and distributing 2.5 billion doses worldwide over the past two decades, Aquestive has historically remained small, with annual revenue of $50 million to $70 million.&nbsp;He said Anaphylm, designed to treat severe allergic reactions with a dissolvable sublingual film instead of an auto-injector, represents the company’s first chance at a broad-market product.Cramer, who first highlighted the stock earlier this month as a speculative pick, pointed to Anaphylm’s potential as an alternative to epinephrine auto-injectors like the EpiPen.Earlier this month, Aquestive said that the FDA has determined an advisory committee meeting is not required for Anaphylm, maintaining the Prescription Drug User Fee Act target action date of January 31, 2026.&nbsp;Oppenheimer raised its price target on Aquestive to $8 from $7 following the announcement, reiterating its ‘Outperform’ rating and noting that investors interpret the FDA decision as increasing the chances of approval.The company has also outlined its regulatory strategy outside the U.S., saying in July that Health Canada granted a meeting to discuss its planned New Drug Submission for Anaphylm and that an initial briefing package has been submitted to the European Medicines Agency.&nbsp;Aquestive said Canada and Europe represent “ideal initial international markets” for the drug, given regulatory alignment and patient need.To prepare for a potential launch, Aquestive has raised about $160 million in financing, which Barber said positions the company to ensure broad outreach to providers, caregivers, and patients once the FDA decision is made.On Stocktwits, retail sentiment for Aquestive was ‘bullish’ amid ‘high’ message volume.One user said that Barber’s appearance on&nbsp;CNBC’s “Mad Money” show&nbsp;was a turning point for Aquestive Therapeutics, saying the CEO “really painted the company in a great light” by backing up Anaphylm’s projected value with current epinephrine market data.&nbsp;<stembedurl>https://stocktwits.com/YaBoyJ313/message/630079945</stembedurl>Another user suggested that Aquestive could become a buyout target within two years of Anaphylm sales, predicting the stock could climb from about $10 to $25 if that scenario&nbsp;were to play out.<stembedurl>https://stocktwits.com/ImPoorAndHungry/message/630067707</stembedurl><a href="https://stocktwits.com/symbol/AQST">Aquestive’s stock</a> has risen 47.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aquestive’s stock (AQST) has risen 47.8% so far in 2025. (Photo credit: Getty Images)

Aquestive Stock Jumps After-Hours As CEO Sees $1B ‘Blockbuster’ Potential For Oral Allergy Film — Retail Sees Stock As Buyout Candidate

Aquestive’s Anaphylm has drawn heightened investor attention after the CEO spotlighted it as the company’s first broad-market product.

Why Aquestive Therapeutics Stock Jumped After-Hours Today

Equity

Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?

Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

Aquestive Therapeutics (AQST) on Thursday said that the U.S. Food and Drug Administration has informed the Company that an advisory committee meeting is not required for Anaphylm Sublingual Film.Anaphylm Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. It is similar in size to a postage stamp and begins to dissolve on contact. No water or swallowing is required for administration.According to Aquestive, Anaphylm has the potential to be the first and only orally delivered epinephrine product for the treatment of severe allergic reactions in the U.S., doing away with the need for injections. The FDA is expected to decide on Aquestive’s application for approval of the sublingual film by January 31, 2026.Aquestive CEO Dan Barber <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-fda-will-not-require-advisory">said</a> that the company is encouraged by the FDA’s decision to waive a meeting and added that the company is “well-positioned” for launch. Shares of the company traded 17% higher in the premarket session.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AQST">AQST stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. A Stocktwits user opined that the stage is now set for approval of Anaphylm.<stembedurl>https://stocktwits.com/BioAmerica/message/627450441</stembedurl>Last month, Aquestive <a href="https://stocktwits.com/news-articles/markets/equity/aquestive-therapeutics-enters-75-million-dollar-funding-agreement/chsRkEVRdOO">said</a> that it entered into a $75 million strategic funding agreement with funds managed by RTW Investments, LP. The financing will become available upon approval of Anaphylm by the FDA and satisfaction of certain refinancing and other customary conditions. Barber said that the financing will support the company through 2027 and allow it to successfully bring Anaphylm to market.RTW, meanwhile, will receive a tiered single-digit percentage of annual net sales of Anaphylm in the U.S. for the treatment of type I allergic reactions, including anaphylaxis, subject to a cap.AQST stock is up by 11% this year but down by about 7% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/ethereum-outperforms-bitcoin-while-broader-crypto-market-slips/chwd22IRdYJ">Ethereum Outperforms Bitcoin, While Broader Crypto Market Slips</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film

 The FDA is expected to decide on Aquestive’s application for approval of the sublingual film by January 31, 2026. 

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Aquestive Therapeutics, Inc. (AQST) on Thursday said that it has entered into a $75 million strategic funding agreement with funds managed by RTW Investments, LP, subject to U.S. Food and Drug Administration (FDA) approval of Anaphylm Sublingual Film.The financing will become available upon approval of Anaphylm by the FDA and satisfaction of certain refinancing and other customary conditions. Aquestive CEO Dan Barber <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/14/3133251/0/en/Aquestive-Therapeutics-Announces-75M-Strategic-Funding-Agreement-with-RTW-to-Support-the-Potential-Launch-of-Anaphylm-epinephrine-Sublingual-Film.html">said</a> that the financing will support the company through 2027 and allow it to successfully bring Anaphylm to market.Under the terms of the agreement, RTW will receive a tiered single-digit percentage of annual net sales of Anaphylm in the U.S. for the treatment of type I allergic reactions, including anaphylaxis, subject to a cap.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AQST">AQST</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of the company traded 6% higher in the pre-market session.<figure class="image"><img style="aspect-ratio:631/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_7_57_19_AM_png_2d91151e35.webp" alt="AQST's Sentiment Meter and Message Volume as of 8:07 a.m. ET on Aug. 14, 2025 | Source: Stocktwits" width="631" height="62"><figcaption>AQST's Sentiment Meter and Message Volume as of 8:07 a.m. ET on Aug. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes uncertainty about funding is out of the way.<stembedurl>https://stocktwits.com/SonOfLionel19/message/625113435</stembedurl>Another, however, opined that the company would need more funds to launch the drug.<stembedurl>https://stocktwits.com/ae1213/message/625112218</stembedurl>Anaphylm Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. It is similar in size to a postage stamp and begins to dissolve on contact. No water or swallowing is required for administration.According to Aquestive, Anaphylm has the potential to be the first and only orally delivered epinephrine product for the treatment of severe allergic reactions in the U.S. The FDA is expected to decide on the candidate by January 31, 2026.Separately, the company also announced pricing of an underwritten offering of 21.25 million shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive are expected to be $85 million.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/14/3133263/0/en/Aquestive-Therapeutics-Announces-Pricing-of-85-Million-Underwritten-Offering-of-Common-Stock.html">said</a> it intends to use the net proceeds received from the offering primarily to advance the launch and commercialization of Anaphylm.AQST stock is up by 13% this year and by about 4% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-inks-up-to-1.3-billion-deal-with-superluminal-medicines/chsRS3IRdO7">Eli Lilly Inks Up To $1.3B Deal With Superluminal Medicines To Develop Obesity Drugs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail

Aquestive CEO Dan Barber said that the $75 million financing will support the company through 2027 and allow it to successfully bring Anaphylm to market.

Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$7.01
Prev Close	$7.34
Open	$7.49
Dividend Yield	0.00%
50-Day Moving Average	$4.95
Beta	1.30
Avg. Volume	4.15M
PE Ratio	-10.64

52-Week High	$7.51
52-Week Low	$2.12
Market Capitalization	$887.95M
EPS (Annual)	-$0.5089
Price to Book	-10.05
Revenue Per Employee	$405,359.16
Enterprise Value/EBITDA	N/A

AQST
Aquestive Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AQST News

AQSTAquestive Therapeutics Inc